Stock Scorecard



Stock Summary for Biomarin Pharmaceutical Inc (BMRN) - $62.65 as of 11/20/2024 7:50:45 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BMRN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BMRN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BMRN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BMRN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BMRN (54 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 4

Latest News for for BMRN

BioMarin : Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia 11/17/2024 2:42:00 AM
Implied Volatility Surging for BioMarin Pharmaceutical ( BMRN ) Stock Options 11/12/2024 1:30:00 PM
CAMP4 Analyst Highlights Rare Disease Platform Potential - Camp4 Therapeutics ( NASDAQ:CAMP ) 11/5/2024 8:06:00 PM
Why BioMarin Pharmaceutical ( BMRN ) is a Top Value Stock for the Long-Term 11/5/2024 2:40:00 PM
Is BioMarin ( BMRN ) a Solid Growth Stock? 3 Reasons to Think "Yes" 11/4/2024 5:45:00 PM
BioMarin ( BMRN ) Upgraded to Buy: Here's Why 11/4/2024 5:00:00 PM
BMRN vs. INCY: Which Stock Is the Better Value Option? 11/4/2024 4:40:00 PM
Why BioMarin Pharmaceutical ( BMRN ) is a Top Growth Stock for the Long-Term 11/4/2024 2:45:00 PM
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth - Biomarin Pharmaceutical ( NASDAQ:BMRN ) 10/30/2024 6:42:00 PM
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised 10/30/2024 3:09:00 PM

Financial Details for BMRN

Company Overview

Ticker BMRN
Company Name Biomarin Pharmaceutical Inc
Country USA
Description BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 62.65
Price 4 Years Ago 87.69
Last Day Price Updated 11/20/2024 7:50:45 PM EST
Last Day Volume 1,893,988
Average Daily Volume 1,462,016
52-Week High 99.56
52-Week Low 61.15
Last Price to 52 Week Low 2.45%

Valuation Measures

Trailing PE 37.33
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 14.02
Free Cash Flow Ratio 12.84
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.27
Total Cash Per Share 4.88
Book Value Per Share Most Recent Quarter 28.41
Price to Book Ratio 2.18
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 4.29
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 8

Share Statistics

Total Shares Outstanding 190,583,000
Market Capitalization 11,940,024,950
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 160.70%
Annual Earnings Growth 18.43%
Reported EPS 12 Trailing Months 1.66
Reported EPS Past Year 1.57
Reported EPS Prior Year 0.95
Net Income Twelve Trailing Months 322,291,000
Net Income Past Year 167,645,000
Net Income Prior Year 141,561,000
Quarterly Revenue Growth YOY 28.30%
5-Year Revenue Growth 10.13%
Operating Margin Twelve Trailing Months 0.15

Balance Sheet

Total Cash Most Recent Quarter 930,444,000
Total Cash Past Year 1,073,810,000
Total Cash Prior Year 1,291,537,000
Net Cash Position Most Recent Quarter -264,183,000
Net Cash Position Past Year -1,113,162,000
Long Term Debt Past Year 2,186,972,000
Long Term Debt Prior Year 2,183,019,000
Total Debt Most Recent Quarter 1,194,627,000
Equity to Debt Ratio Past Year 0.69
Equity to Debt Ratio Most Recent Quarter 0.82
Total Stockholder Equity Past Year 4,951,549,000
Total Stockholder Equity Prior Year 4,603,156,000
Total Stockholder Equity Most Recent Quarter 5,413,396,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 300,882,000
Free Cash Flow Per Share Twelve Trailing Months 1.58
Free Cash Flow Past Year 51,648,000
Free Cash Flow Prior Year 44,362,000

Options

Put/Call Ratio 0.29
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.70
MACD Signal -1.65
20-Day Bollinger Lower Band 57.83
20-Day Bollinger Middle Band 77.31
20-Day Bollinger Upper Band 96.80
Beta 0.31
RSI 25.91
50-Day SMA 83.46
150-Day SMA 87.85
200-Day SMA 86.03

System

Modified 11/20/2024 7:43:32 PM EST